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OBJECTIVE—Uncoupling protein 2 (UCP2) is a physiological
downregulator of reactive oxygen species generation and plays
an antiatherogenic role in the vascular wall. A common variant in
the UCP2 promoter (866GA) modulates mRNA expression,
with increased expression associated with the A allele. We
investigated association of this variant with coronary artery
disease (CAD) in two cohorts of type 2 diabetic subjects.
RESEARCH DESIGN AND METHODS—We studied 3,122
subjects from the 6-year prospective Non–Insulin-Dependent
Diabetes, Hypertension, Microalbuminuria, Cardiovascular
Events, and Ramipril (DIABHYCAR) Study (14.9% of CAD inci-
dence at follow-up). An independent, hospital-based cohort of
335 men, 52% of whom had CAD, was also studied.
RESULTS—We observed an inverse association of the A allele
with incident cases of CAD in a dominant model (hazard risk 0.88
[95% CI 0.80–0.96]; P  0.006). Similar results were observed for
baseline cases of CAD. Stratification by sex confirmed an allelic
association with CAD in men, whereas no association was
observed in women. All CAD phenotypes considered—myocar-
dial infarction, angina pectoris, coronary artery bypass graft
(CABG), and sudden death—contributed significantly to the
association. Results were replicated in a cross-sectional study of
an independent cohort (odds ratio 0.47 [95% CI 0.25–0.89]; P 
0.02 for a recessive model).
CONCLUSIONS—The A allele of the866GA variant of UCP2
was associated with reduced risk of CAD in men with type 2
diabetes in a 6-year prospective study. Decreased risk of myo-
cardial infarction, angina pectoris, CABG, and sudden death
contributed individually and significantly to the reduction of CAD
risk. This association was independent of other common CAD
risk factors. Diabetes 57:1063–1068, 2008
Cardiovascular disease accounts for up to 80% ofthe deaths of type 2 diabetic patients (1). Dia-betic patients have a threefold higher risk thannondiabetic individuals of developing athero-
sclerosis and its clinical complications, such as stroke,
myocardial infarction, and peripheral vascular disease (2).
Arterial hypertension and dyslipidemia frequently coexist
with diabetes and contribute to the increased prevalence
of cardiovascular disease in diabetic patients. However,
type 2 diabetes is an independent risk factor for cardio-
vascular disease (3). The molecular mechanisms linking
type 2 diabetes and atherosclerosis remain unclear (4).
Several metabolic dysfunctions associated with type 2
diabetes have been proposed to play a role in the acceler-
ation of atherosclerosis, including hyperinsulinemia, hy-
perglycemia, increased formation of advanced glycation
end products, platelet hyperaggregability, coagulation ab-
normalities, endothelial dysfunction, and increased oxida-
tive stress (4). Particularly, increased oxidative stress in
vascular cells plays a key role in the formation of ather-
oma (5) and in the instability of the atherosclerotic plaque,
a crucial step in the occurrence of acute coronary events
(6).
Uncoupling protein 2 (UCP2) functions as a physiolog-
ical downregulator of reactive oxygen species (ROS) gen-
eration in endothelial and smooth muscle cells of the
vascular wall and in macrophages (7–11). Several studies
have shown that UCP2 plays an antiatherogenic role in the
vascular wall (8,9,11) and may improve tolerance to car-
diac ischemia (12). A series of clinical investigations have
shown associations of the866GA (rs659366) functional
single nucleotide polymorphism (SNP) in the promoter
region of UCP2 with phenotypes related to obesity (13),
glucose homeostasis (14–16), and dyslipidemia (17). In the
present study, we investigated the association of this
variant with coronary artery disease (CAD) in type 2
diabetic patients.
RESEARCH DESIGN AND METHODS
Prospective study. The Non-Insulin-Dependent Diabetes, Hypertension, Mi-
croalbuminuria, Cardiovascular Events, and Ramipril (DIABHYCAR) Study
was a 6-year double-blind multicenter multinational clinical trial conducted in
4,912 men and women with type 2 diabetes aged50 years or older at baseline
and selected on the basis of a persistent micro- or macroalbuminuria (urinary
albumin concentration [UAC] 20 mg/l) without renal failure (serum creati-
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nine 150 mol/l). The trial tested in a parallel design and versus placebo
whether a low dose of ramipril (1.25 mg/day) able to reduce UAC would also
reduce cardiovascular and/or renal events, such as myocardial infarction,
stroke, acute heart failure, end-stage renal failure, and cardiovascular death.
Study design, methods, and results of the trial (which were negative regarding
the drug effect) were published previously (18,19). For the purpose of the trial,
myocardial infarction was diagnosed as the occurrence of at least two of three
of the following criteria: constrictive chest pain lasting 20 min or longer,
increased serum creatinine phosphokinase and/or troponine levels, or typical
electrocardiographic changes. Sudden death was defined as death occurring
instantaneously or within 1 h after the onset of new cardiac symptoms
(arrhythmia and myocardial infarction) or nonwitnessed death, when the
body was found and no cause of death could be discovered. Fatal stroke was
not included in this group. All events were adjudicated by an independent
event committee (18). DNA banking was undertaken for the 3,137 participants
recruited in France. All participants gave written informed consent. The study
protocol was approved by the Angers University Hospital Ethics Committee.
In the present investigation, we studied 3,122 French type 2 diabetic
patients from the original DIABHYCAR cohort. Age at baseline was 66  8
years (means  SD), and 73% of patients were men. Also at baseline, 172
subjects (5.5%) had a previous history of myocardial infarction, and 376
subjects (12%) had a diagnosis of angina pectoris. Myocardial infarction
occurred in 95 patients (3%) during the trial, including 10 subjects with history
of myocardial infarction at baseline. Coronary artery bypass graft (CABG) was
performed in 295 subjects during the trial, including 80 subjects with previous
myocardial infarction at baseline or during the study. Sudden death occurred
in 137 subjects (4.4%) during the trial, including 25 subjects with previous
myocardial infarction at baseline or during the study. For the purpose of this
investigation, baseline cases of CAD included the cases of myocardial
infarction and/or angina pectoris. Incident cases of CAD included the cases of
myocardial infarction or of sudden death or the cases of a history of CABG
during the follow-up. Supplemental Table 1, which is detailed in the online
appendix (available at http://dx.doi.org/10.2337/db07-1292), shows the strati-
fication of incident cases of CAD according to CAD baseline status.
Cross-sectional study. We have studied a group of 335 French Caucasian
men with type 2 diabetes recruited at the Departments of Diabetology of
Necker and Cochin Hospitals (NCH) in Paris. The presence or absence of CAD
was documented either by a history of myocardial infarction or CABG or by
the systematic assessment of myocardial ischemia in asymptomatic patients.
In the latter case, patients with cardiovascular risk factors underwent a stress
test (stress electrocardiogram, stress thallium-201 single photon emission
computed tomography, or dobutamine echocardiography). Patients with a
positive stress test underwent coronary angiography. CAD was considered
present if significant stenosis (50%) was present in at least one major vessel
or branch. CAD was considered absent in patients with normal stress test or
with no significant coronary stenosis at angiography. Detailed procedures of
stress tests and angiography have been previously reported (20). Overall, 174
patients with CAD (35% with a previous history of myocardial infarction or
CABG and 65% diagnosed by coronary angiography) and 161 patients without
CAD were included in the present study. Subjects were considered to have























FIG. 1. Kaplan-Meier survival (disease-free) curves for the DIABHY-
CAR cohort during follow-up according to genotype. Survival (y) axis
represents absence of CAD defined as myocardial infarction, CABG, or
sudden death. The cumulated incidence of CAD can be computed as
(100%  survival).
TABLE 1
Characteristics of DIABHYCAR cohorts at baseline according to CAD incidence status
Incident CAD
P valueYes No
Patients (n) 464 2,658 —
Men (%) 80 71 0.0001
Age (years) 67 8 65  8 0.0001
Age at diagnosis of diabetes (years) 56 10 55  10 0.11
Known duration of diabetes (years) 11 8 10  8 0.005
Fasting plasma glucose (mmol/l) 9.6 2.9 9.5  3.1 0.53
A1C (%) 8.0 1.8 7.8  1.8 0.02
BMI (kg/m2) 28.9 4.4 29.5 4.7 0.01
Ponderal status: lean/overweight/obese (%)* 13/49/38 12/43/45 0.03
Triglycerides (mmol/l) 2.38 1.32 2.19 1.44 0.0003
Total cholesterol (mmol/l) 5.97 1.10 5.76  1.06 0.0002
LDL cholesterol (mmol/l)† 3.68 0.90 3.50 0.88 0.0006
HDL cholesterol (mmol/l) 1.25 0.31 1.33 0.36 0.0001
Creatinine clearance (ml/min) 80 27 87  30 0.0001
Urinary albumin excretion (mg/l) 391 1207 202  446 0.0001
UAE: microalbuminuria/macroalbuminuria (%)‡ 68/32 78/22 0.0001
Arterial hypertension (%)§ 62 55 0.01
Tobacco smoking (%) 15 14 0.67
Randomization group: ramipril (%)¶ 47 50 0.37
Previous myocardial infarction (%) 13 4 0.0001
Angina pectoris (%) 23 10 0.0001
Data are means  SD. CAD represents the incident cases of myocardial infarction, CABG, or sudden death during the study. Statistics of
quantitative parameters are Students t test performed with log-transformed data. *Ponderal status: lean, BMI 25 kg/m2; overweight, 25
kg/m2  BMI  30 kg/m2; obese, BMI 30 kg/m2. †Data available for 353 subjects with CAD and 2,145 subjects without CAD. ‡UAE:
microalbuminuria, 20 mg/l  UAE  200 mg/l; macroalbuminuria, UAE 200 mg/l. §Arterial hypertension: systolic blood pressure 140
mmHg and/or diastolic blood pressure90 mmHg; or systolic blood pressure and diastolic blood pressure below these values in the presence
of antihypertensive medication and history of hypertension. ¶Randomization group in the original DIABHYCAR study ramipril versus
placebo.
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lesterol levels if current or pretreatment plasma levels were 1.70, 3.35, or
1.02 mmol/l, respectively (21). Arterial hypertension was defined as systolic
blood pressure 140 mmHg or diastolic blood pressure 90 mmHg (22) or by
the presence of antihypertensive therapy. Creatinine clearance was computed
with the Cockcroft formula (23). All participants gave written informed
consent. The study was approved by the ethics committee of Hoˆpital Necker
(CCPPRB Paris Necker).
DNA studies. The SNP at position 866 in the promoter region of the UCP2
gene (rs659366) was genotyped using the Assay by Design kit from Applied
Biosystems. The conditions for TaqMan reaction were as follows: 50°C for 2
min, 95°C for 10 min, and 45 cycles of 95°C for 15 s and 66°C for 1 min.
Statistical analyses. Results are expressed as means  SD. Differences
between groups were assessed by Student’s t test, contingency table 2 test,
and Fisher’s exact test. Before genotype-related statistical analyses were
performed, it was verified that genotypes were in Hardy-Weinberg equilibrium
in all groups of subjects. Genotype associations with CAD were assessed by
regression models. Cox proportional hazards survival regression analyses
were used to examine the effect of explanatory variables on time-related
survival (disease-free) rates in prospective analyses. Kaplan-Meier curves
were used to plot survival (disease-free) rates over time according to
genotype. Logistic regression analyses were used for cross-sectional analyses.
Hazard ratios (HRs) or odds ratios (ORs), respectively, with their 95% CIs
were computed in these analyses for the minor A allele. For dominant (XA vs.
GG genotypes) and recessive (AA vs. XG genotypes) models, HRs and/or ORs
were considered to be 1 for GG or XG genotypes, respectively. For the
codominant model, genotype data were coded as the number of A-allele
copies (0, 1, or 2), and HR was computed for the number of A alleles as a
quantitative variable (1 vs. 0 and 2 vs. 1 copies, with the lower number of
copies of each pair considered to present an OR of 1). Interaction between sex
and genotype was assessed by including in the regression model a “crossed”
compound covariable (sex/genotype). Stratification by sex of genotype-
related effects was then performed by nesting the genotype variable within the
sex variable in the regression analysis. This results in the computation of
statistical effects for men and women separately and adjusted for multiple
comparisons due to the stratification by sex. Adjustments for other clinical
and biological parameters were carried out by including these parameters as
covariables in the regressive model. Data were log transformed for the
analyses when the normality of the distribution was rejected by the Shapiro-
Wilk W test. P  0.05 was considered significant. Statistics were performed
with the JMP software (SAS Institute, Cary, NC).
RESULTS
Prospective study: DIABHYCAR cohort. The incidence
of CAD during the follow-up of the French subset of the
DIABHYCAR cohort was 14.9%. CAD events comprised 95
cases of myocardial infarction, 295 cases of CABG, and
137 cases of sudden death reported in 464 subjects. Main
baseline characteristics of subjects with or without CAD
during the follow-up (incident cases) are shown in Table 1.
Known cardiovascular risk factors, such as the male sex,
dyslipidemia, arterial hypertension, decreased renal func-
tion, and albuminuria, were more frequent or more severe
in subjects with CAD compared with subjects without
CAD.
Incidence of CAD according to genotype was 17.0% for
GG, 13.8% for GA, and 11.9% for AA (Fig. 1). Cox propor-
tional hazards survival regression analyses showed an
inverse association of the A allele with the incidence of
CAD in a dominant model (HR 0.88 [95% CI 0.80–0.96]; P
0.006) (Table 2). A significant interaction between geno-
type and sex (P  0.008) was observed in this association
with CAD. Stratification by sex confirmed the allelic
association with CAD in men, whereas no association was
observed in women (Table 2). The association persisted
after adjustment for allocation group in the original DIAB-
HYCAR trial (drug or placebo), age, BMI, total cholesterol,
HDL cholesterol, triglycerides, urinary albumin excretion,
creatinine clearance, A1C, duration of diabetes, and arte-
rial hypertension (Table 2). There was no interaction
between the treatment group in the original DIABHYCAR
study and the effect of genotype on CAD. To assess which
CAD phenotypes contributed to this association, we com-
puted individual HRs for cases of myocardial infarction or
CABG or sudden death by excluding from the calculations
for each phenotype the other incident cases of CAD. HRs
for the A allele in men were 0.71 (0.56–0.90) (P  0.004)
for myocardial infarction, 0.88 (0.78–0.99) (P  0.05) for
CABG, and 0.82 (0.67–0.99) (P  0.04) for sudden death.
Analyses in a codominant model were also significant (P
0.02 for the whole population; P  0.007 for men) but only
confirmed a dominant effect. The HR for the presence of
one A allele (AG vs. GG) in men was 0.73 (0.59–0.90), with
no significant additional effect for the second A allele (AA
vs. AG, 0.95 [0.66–0.1.33]). Similar association in a domi-
nant model was observed when we considered the preva-
lent cases of CAD at baseline, defined as a previous history
of myocardial infarction or angina pectoris (Table 3).
To investigate the role of possible intermediate pheno-
types in these allelic associations with CAD, we compared
clinical and biological profiles at baseline according to
genotype (Supplemental Table 2). Age of diagnosis of
diabetes, severity of hyperglycemia, BMI and ponderal
status, renal function, prevalence of arterial hypertension,
plasma levels of triglycerides, total cholesterol, and HDL
cholesterol were similar in carriers of different genotypes.
LDL cholesterol levels were slightly but significantly lower
TABLE 2
Genotype frequency and incidence of CAD in the DIABHYCAR cohort
Subjects CAD
866GA:N (genotype frequency) A allele in a dominant model
GG GA AA
Unadjusted model Adjusted model*
HR (95% CI)
P
value HR (95% CI)
P
value
All Yes 217 (0.468) 197 (0.424) 50 (0.108)
No 1,058 (0.398) 1,230 (0.463) 370 (0.139) 0.88 (0.80–0.96) 0.006 0.87 (0.80–0.96) 0.005
Men Yes 179 (0.480) 154 (0.413) 40 (0.107)
No 744 (0.390) 903 (0.473) 261 (0.137) 0.85 (0.77–0.94) 0.002 0.84 (0.76–0.93) 0.001
Women Yes 38 (0.418) 43 (0.472) 10 (0.110)
No 314 (0.419) 327 (0.436) 109 (0.145) 1.00 (0.82–1.24) 0.98 1.04 (0.84–1.29) 0.72
CAD: incident cases of myocardial infarction, CABG or sudden death. HRs for the A-allele in a dominant model (XA vs. GG) determined by
Cox proportional hazards survival regression analyses. Time to event was defined either as the number of days of follow-up until the
occurrence of a CAD event for subjects with CAD or as the duration of follow-up for right-censored subjects without CAD at the end of
follow-up. Computations performed without adjustment for covariables or *adjusted for allocation group in the original DIABHYCAR trial
(drug or placebo), age, BMI, total cholesterol, HDL cholesterol, triglycerides, urinary albumin excretion, creatinine clearance, A1C, duration
of diabetes, and arterial hypertension.
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in carriers of the A allele: 3.50  0.89 vs. 3.57  0.87
mmol/l (P  0.02), respectively, for XA and GG subjects.
Cross-sectional study: NCH cohort. Main clinical char-
acteristics of subjects with or without CAD are shown in
Supplemental Table 3. Cardiovascular risk factors, such as
dyslipidemia, arterial hypertension, decreased renal func-
tion, albuminuria, and a history of cigarette smoking, were
more frequent or more severe in subjects with CAD. A
logistic regression analysis was performed to assess asso-
ciation of genotype with CAD (Table 4). We observed an
inverse association of the A allele with CAD in a recessive
model (OR 0.47 [0.25–0.89]; P 0.02). This genotype effect
remained significant when adjusted for other individual
risk factors (LDL cholesterol, HDL cholesterol, arterial
hypertension, creatinine clearance, and albuminuria).
These associations are in keeping with genotype-related
prevalences of CAD: 56 vs. 53 vs. 36% in G allele homozy-
gous, heterozygous, and A allele homozygous subjects,
respectively.
DISCUSSION
We have observed in two independent cohorts of French
Caucasian subjects that the common866GA SNP in the
UCP2 promoter region strongly modulates the risk of CAD
in type 2 diabetic men. The first cohort was recruited for a
multicenter prospective clinical trial. Inverse associations
of the A allele with both baseline and incident cases of
CAD were observed in a dominant model with a 12–25%
decrease in CAD risk for A allele carriers. The four types
of CAD events that we have considered, namely, myocar-
dial infarction, angina pectoris, CABG, and sudden death,
contributed significantly to these results. Interestingly,
these associations showed interaction with sex and were
observed in men but not in women. We have no estab-
lished explanation for this lack of association in women,
but it is not possible to exclude true sex-related biological
differences in UCP2 protection against CAD.
These results were confirmed in a smaller, hospital-
based cohort recruited from a single Diabetes department
and consisting of type 2 diabetic men with a history of
myocardial event (infarction or CABG) or who underwent
a systematic assessment of myocardial ischemia. A allele
homozygosis was associated with a 50% decrease in the
risk of CAD in the NCH cohort. Apparently, this effect is
larger than the 25% decrease observed, for instance, for
the baseline cases of CAD in men of the DIABHYCAR
cohort, also computed by OR. However, the wide CIs
associated with both ORs preclude the drawing of such a
conclusion. It is also noteworthy that A allele association
with decreased risk of CAD in men was observed for
different genetic models in the two cohorts of our study: in
dominant models for the DIABHYCAR cohort and in a
recessive model for the NCH cohort. We do not have an
established explanation for this observation, but it could
be related to phenotype differences due to different
study design and CAD ascertainment methods in the
two cohorts.
Previous studies have shown that the 866GA SNP is
a functional polymorphism (13,14). The A allele has been
associated with enhanced adipose tissue mRNA expres-
sion in vivo and has been shown to result in increased
transcription of a reporter gene in a human adipocyte cell
line (13). Studies in pancreatic -cell line INS1-E have
shown that the pancreatic transcription factor PAX6 pref-
erentially binds to and more effectively transactivates the
A allele (14). To our knowledge, allele-related expression
studies in cell types directly implicated in the atheroscle-
rosis process or plaque stability are not available.
Several investigations have established a link between
UCP2 and atherosclerosis. UCP2 is a physiological down-
regulator of ROS generation in endothelial and smooth
muscle cells of the vascular wall, in macrophages (7–11),
and in cardiomyocytes (24). It has antiatherogenic effects
in the arterial wall (8,9,11) and could protect cardiomyo-
cytes from oxidative stress–induced cell death by reducing
ROS production in mitochondria (24). Blanc et al. (8)
TABLE 3
Genotype frequency and prevalence of CAD at baseline in the DIABHYCAR cohort
Subjects CAD
866GA:N (genotype frequency) A allele in a dominant model
GG GA AA
Unadjusted model Adjusted model*
OR (95% CI)
P
value OR (95% CI)
P
value
All Yes 216 (0.451) 197 (0.411) 66 (0.138)
No 1059 (0.401) 1230 (0.465) 354 (0.134) 0.81 (0.67–0.98) 0.04 0.81 (0.66–0.99) 0.04
Men Yes 179 (0.469) 149 (0.390) 54 (0.141)
No 744 (0.392) 908 (0.478) 247 (0.130) 0.73 (0.59–0.91) 0.005 0.74 (0.59–0.92) 0.008
Women Yes 37 (0.381) 48 (0.495) 12 (0.124)
No 315 (0.423) 322 (0.433) 107 (0.144) 1.19 (0.77–1.85) 0.43 1.13 (0.71–1.80) 0.61
CAD: history of myocardial infarction or angina pectoris at baseline. OR for the A allele in a dominant model (XA vs. GG) determined in
logistic regression analyses. Computations performed without adjustment for covariables or *adjusted for age, BMI, total cholesterol, HDL
cholesterol, triglycerides, urinary albumin excretion, creatinine clearance, A1C, duration of diabetes, and arterial hypertension.
TABLE 4
Genotype frequency and prevalence of CAD in the NCH cohort
866GA:N (genotype frequency) A allele in a recessive model
GG GA AA OR (95% CI) P value
With CAD 76 (0.437) 81 (0.465) 17 (0.098) 0.47 (0.25–0.89) 0.02
Without CAD 60 (0.373) 71 (0.441) 30 (0.186)
OR for the A allele (AA vs. GX) determined in logistic regression analyses.
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studied LDL receptor–deficient mice fed an atherogenic
diet, an animal model of accelerated atherosclerosis. Ani-
mals were irradiated and then transplanted with bone
marrow from either UCP2-deficient mice (Ucp2/) or
wild-type mice (Ucp2	/	). Larger atherosclerotic lesions
with a more severe plaque phenotype (increased macro-
phage accumulation, apoptosis, and histological markers
of enhanced oxidative stress along with decreased colla-
gen content) were observed in the thoracic aorta of
Ucp2/ transplanted mice compared with Ucp2	/	 trans-
planted mice. Park et al. (11) showed that overexpression
of UCP2 in human vascular smooth muscle cells reversed
the increase in ROS production and cellular proliferation
and migration elicited by high glucose and angiotensin II
concentrations in the culture medium. Moreover, it was
recently shown in mouse models that UCP2 positively
modulates adiponectin gene expression and influences
circulating adiponectin levels (25). Adiponectin has many
protective actions in the initiation and progression of
atherosclerosis by means of direct anti-inflammatory and
anti-atherogenic effects (26,27). All of these results suggest
a protective role for UCP2 against atherosclerosis and
could explain the protective effect of the A allele observed
in our study.
A series of clinical studies showed associations of this
polymorphism with several phenotypes related to obesity,
diabetes, insulin sensitivity, insulin secretion, and dyslipi-
demia (13–17,28). We have observed in the DIABHYCAR
cohort slightly decreased LDL cholesterol levels in A allele
carriers compared with GG carriers. However, it is inter-
esting to note that the protection against CAD afforded by
the A allele in our study was independent from effects on
other known cardiovascular risk factors, including obe-
sity, arterial hypertension, and dyslipidemia. Our results
contrast with those in the study by Dhamrait et al. (29) in
a cohort of healthy men prospectively studied for 10 years.
In that study, A allele homozygosis doubled CAD risk after
adjustment for other risk factors. Moreover, in that study,
the A allele was also associated with obesity, which also
contrasts with results from two independent cohorts of
nondiabetic subjects, in whom a reduction in the preva-
lence of obesity was observed for A allele carriers (13).
The reasons for all of these discrepancies remain unclear.
Regarding obesity, a protective effect of A allele would be
in keeping with the observation of inverse correlations
between UCP2 mRNA expression in human adipose tissue
of nondiabetic subjects and BMI, percentage of body fat,
and blood levels of leptin, insulin, and triglyceride (30).
In summary, we found that the A allele of the 866GA
SNP in the UCP2 promoter region was associated with a
significantly lower risk of CAD in type 2 diabetic men. This
effect was independent of effects of other risk factors,
such as age, duration of diabetes, dyslipidemia, arterial
hypertension, proteinuria, and smoking. The mechanisms
underlying this allelic association need to be investigated
in further studies. They could be related to a modulation of
antiatherogenic effects of UCP2 in the vascular wall.
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